Souvin Pharmaceuticals (India) Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 09-12-2024
- Paid Up Capital ₹ 1.00 Cr
as on 09-12-2024
- Company Age 15 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.00 Cr
as on 09-12-2024
- Revenue 28.02%
(FY 2022)
- Profit 24.08%
(FY 2022)
- Ebitda 140.52%
(FY 2022)
- Net Worth 10.58%
(FY 2022)
- Total Assets -11.76%
(FY 2022)
About Souvin Pharmaceuticals (India)
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company currently has active open charges totaling ₹1.00 Cr.
Rajeshwari Biradar, Sidagouda Biradar, and Vishnu Halnor serve as directors at the Company.
- CIN/LLPIN
U24230PN2009PTC134023
- Company No.
134023
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 May 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Souvin Pharmaceuticals (India)?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vishnu Halnor  | Director | 13-Mar-2014 | Current |
| Rajeshwari Biradar | Director | 26-May-2009 | Current |
| Sidagouda Biradar | Director | 26-May-2009 | Current |
Financial Performance of Souvin Pharmaceuticals (India).
Souvin Pharmaceuticals (India) Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 28.02% increase. The company also saw a substantial improvement in profitability, with a 24.08% increase in profit. The company's net worth Soared by an impressive increase of 10.58%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Souvin Pharmaceuticals (India)?
Unlock access to Souvin Pharmaceuticals (India)'s control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
S.T. Biradar Engineers And Contractors Private LimitedActive 19 years 5 monthsRajeshwari Biradar and Sidagouda Biradar are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Karnataka Bank Ltd. Creation Date: 11 Jun 2010 | ₹1.00 Cr | Open |
How Many Employees Work at Souvin Pharmaceuticals (India)?
Unlock and access historical data on people associated with Souvin Pharmaceuticals (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Souvin Pharmaceuticals (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Souvin Pharmaceuticals (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
